Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247588 | 0.85 | AURKA (0.55) | AURKAMAPK10KDRLRRK2JAK2 | |
| SCHEMBL31247430 | 0.84 | AURKA (0.40) | AURKAMAPK10KDRLRRK2ALDH1A1 | |
| SCHEMBL31247617 | 0.81 | AURKA (0.57) | AURKAMAPK10KDRLRRK2NPC1 | |
| SCHEMBL31247692 | 0.81 | AURKA (0.47) | AURKAKDRMAP4K4GSK3BLRRK2 | |
| SCHEMBL31247594 | 0.80 | AURKA (0.43) | AURKAMAPK10KDRLRRK2ALDH1A1 | |
| SCHEMBL31247770 | 0.79 | AURKA (0.43) | AURKAKDRLRRK2KDM4EMEN1 | |
| SCHEMBL31247399 | 0.77 | AURKA (0.48) | AURKAMAPK10KDRCDK5LRRK2 | |
| SCHEMBL31247412 | 0.77 | LRRK2 (0.47) | AURKALRRK2 | |
| SCHEMBL31247722 | 0.75 | TYK2 (0.63) | MAPK10KDRMAP4K4ABL1LCK | |
| SCHEMBL31247590 | 0.75 | MAPK10 (0.43) | MAPK10KDRMAP4K4ABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12358904-B2 | Inhibitors of TYK2 | Atomwise Inc. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| US-20240417396-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-19 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417396-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | AURKA 150/4885MAPK10 309/4885KDR 1792/4885 |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | AURKA 1353/4885MAPK10 480/4885KDR 1579/4885 |
| US-12358904-B2 | Inhibitors of TYK2 | TYK2, LCK, JAK2 | AURKA 150/4885MAPK10 309/4885KDR 1792/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | AURKA 150/4885MAPK10 309/4885KDR 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.